Home > Publications Database > Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de > print

001     282542
005     20260105130708.0
024 7 _ |a pmid:40817636
|2 pmid
024 7 _ |a 10.1002/bcp.70194
|2 doi
024 7 _ |a 0306-5251
|2 ISSN
024 7 _ |a 1365-2125
|2 ISSN
024 7 _ |a pmc:PMC12648363
|2 pmc
037 _ _ |a DZNE-2025-01305
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lepenies, Laura K.
|0 0009-0002-1186-355X
|b 0
245 _ _ |a Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de
260 _ _ |a Oxford
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765543088_18547
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Drugs with anticholinergic effects are often considered as potentially inappropriate medications, especially for older patients, and deprescribing such drugs may improve cognitive function. The aim was to investigate the effectiveness of counselling on drug risks as part of a multimodal intervention to prevent cognitive decline.The AgeWell.de study, a multi-centre, cluster-randomized controlled study, was conducted in 123 German general practices between June 2018 and January 2022. The study included a multicomponent intervention programme for patients at increased risk of dementia, delivered over a 2-year period. As part of the medication optimisation intervention, patient data and medication records were screened to identify medication risks and provide recommendations to general practitioners.In total, 808 patients with complete data were included in the present analysis (intervention group = 374, control group = 434). At baseline, 132 (16.8%) patients had at least one anticholinergic prescription. After 2 years, approximately one-third of these patients no longer received drugs with anticholinergic effects. There were no significant differences between the intervention and control groups, with 67.6% and 72.1%, respectively, continuing to take drugs with anticholinergic effects (P = 0.57). Patients reported anticholinergic symptoms more frequently when taking any medication (5.0% vs 33.8%), and even more so when taking drugs with anticholinergic effects (56.1%). Deprescribing of all drugs with anticholinergic effects was non-significantly higher in patients who reported at least one anticholinergic symptom compared to patients without any anticholinergic symptoms (58.6% vs 54.1%).The medication optimisation intervention did not entail significant differences in anticholinergic deprescribing between the groups.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 7 |a anticholinergic drugs
|2 Other
650 _ 7 |a dementia
|2 Other
650 _ 7 |a deprescribing
|2 Other
650 _ 7 |a lifestyle intervention
|2 Other
650 _ 7 |a randomized controlled study
|2 Other
650 _ 7 |a Cholinergic Antagonists
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cholinergic Antagonists: adverse effects
|2 MeSH
650 _ 2 |a Cholinergic Antagonists: administration & dosage
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Dementia: prevention & control
|2 MeSH
650 _ 2 |a Dementia: chemically induced
|2 MeSH
650 _ 2 |a Dementia: epidemiology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Deprescriptions
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Inappropriate Prescribing: prevention & control
|2 MeSH
650 _ 2 |a Germany
|2 MeSH
650 _ 2 |a Counseling: methods
|2 MeSH
650 _ 2 |a General Practice
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: prevention & control
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: chemically induced
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
700 1 _ |a Seidling, Hanna M.
|0 0000-0002-1215-634X
|b 1
700 1 _ |a Pabst, Alexander
|b 2
700 1 _ |a Luppa, Melanie
|b 3
700 1 _ |a Döhring, Juliane
|b 4
700 1 _ |a Williamson, Martin
|b 5
700 1 _ |a Frese, Thomas
|b 6
700 1 _ |a Gensichen, Jochen
|b 7
700 1 _ |a Hoffmann, Wolfgang
|0 P:(DE-2719)2000040
|b 8
|u dzne
700 1 _ |a Kaduszkiewicz, Hanna
|b 9
700 1 _ |a König, Hans-Helmut
|b 10
700 1 _ |a Thyrian, Jochen René
|0 P:(DE-2719)2290613
|b 11
|u dzne
700 1 _ |a Wiese, Birgitt
|b 12
700 1 _ |a Riedel-Heller, Steffi G.
|b 13
700 1 _ |a Czock, David
|0 0000-0003-1217-5134
|b 14
773 _ _ |a 10.1002/bcp.70194
|g Vol. 91, no. 12, p. 3489 - 3500
|0 PERI:(DE-600)1498142-7
|n 12
|p 3489 - 3500
|t British journal of clinical pharmacology
|v 91
|y 2025
|x 0306-5251
856 4 _ |u https://pub.dzne.de/record/282542/files/DZNE-2025-01305.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/282542/files/DZNE-2025-01305.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:282542
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000040
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2290613
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRIT J CLIN PHARMACO : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-16
920 1 _ |0 I:(DE-2719)1510600
|k AG Hoffmann
|l Translational Health Care Research
|x 0
920 1 _ |0 I:(DE-2719)1510800
|k AG Thyrian
|l Interventional Health Care Research (IHCR)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1510600
980 _ _ |a I:(DE-2719)1510800
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21